Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER3 dendritic cell vaccine

A type-1-polarized dendritic cell (DC1)-based cancer vaccine against the tumor-associated antigen (TAA) human epidermal growth factor receptor 3 (HER3; ERBB3), with potential immunomodulatory and antineoplastic activities. Upon intratumoral administration of the anti-HER3 DC vaccine, the immune system gets exposed to HER3, which may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER3-positive tumor cells. This may result in tumor cell death and decreased tumor growth. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is overexpressed by a variety of cancers.
Synonym:anti-HER-3 DC vaccine
anti-HER3 DC vaccine
anti-HER3 DC1 vaccine
HER3-primed DC vaccine
HER3-primed DC1 vaccine
HER3-primed dendritic cell vaccine
Search NCI's Drug Dictionary